Spike Protein News and Research

RSS

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

A team of scientists from the United States has recently engineered a pre-existing anti-severe acute respiratory syndrome coronavirus (SARS-CoV) neutralizing antibody to increase its binding affinity for the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The engineered antibody demonstrates high potency in neutralizing SARS-CoV-2 and preventing infection in animals.

31 May 2021

Inflammatory brain injury higher in men with acute COVID-19, finds study

The COVID-19 pandemic has been associated with both short- and long-term neurologic complications, including stroke, brain fog and persistent tiredness. A new study concludes that the effects of SARS-CoV-2 on the central nervous system (CNS) are due to the endothelial injury and inflammation that this produces in the brain.

31 May 2021

SARS-CoV-2 genome mutations display convergent evolution indicating strong adaptive advantages

A recent report by a team of researchers focused on the extent of convergent evolution in the SARS-CoV-2 spike (S) protein. The report confirms that top SARS-CoV-2 lineages of concern have the most convergent spike protein mutations. This indicates their fundamental adaptive advantage.

31 May 2021

Corilagin: could a plant compound used in Chinese herbal medicine help prevent COVID-19?

The study, published in the journal Phytomedicine, characterized an active compound, corilagin (a derivative from Phyllanthus urinaria), as potential SARS-CoV-2 entry inhibitors for its preventive application in daily antiviral hygiene products.

31 May 2021

Researchers identify defensins as potential anti-SARS-CoV-2 agents

A recent study conducted at the Ohio State University, USA, and the Fudan University, China, has revealed that alpha-defensin human neutrophil peptide 1 (HNP1), a cationic antimicrobial peptide, can prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from infecting cells by destabilizing the viral spike protein and disrupting spike-mediated viral envelop – host cell membrane fusion.

31 May 2021

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization

A team of scientists from France has recently conducted a study to evaluate the sensitivity of the B.1.617 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to antibody-mediated neutralization.

31 May 2021

New LNP-based mRNA vaccine candidate protects against lethal SARS-CoV-2 in preclinical trials

A new study, published in Nano Letters, describes an effective new COVID-19 vaccine candidate based on a messenger ribonucleic acid (mRNA) platform.

28 May 2021

Loss of gut epithelial barrier responsible for COVID-19-related MIS-C in children, suggests study

A new paper in the Journal of Clinical Investigation reports that this condition is due to damage to the gut, mediated by a decrease in the protein called zonulin, which is responsible for the integrity of the gut epithelial barrier. Reduced zonulin levels are found in several inflammatory and autoimmune conditions.

28 May 2021

Researchers identify a novel SARS-CoV-2 variant (with the V1230L mutation) in West Bengal, India

Researchers analyzed 2,000 viral genomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19) – sequences obtained from India and found a new variant that could be more infectious and transmissible.

28 May 2021

Study supports single-dose COVID-19 vaccine strategy for previously infected individuals

Researchers in the Netherlands have provided evidence that a single dose of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine is sufficient to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among people who have already been infected with the virus.

28 May 2021

Identifying SARS-CoV-2 epitopes targeted by current vaccination could help improve future vaccines

Researchers in the United States have identified antibody-inducing epitopes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals vaccinated against coronavirus disease 2019 (COVID-19) that could be used for future diagnostics, therapeutics, and vaccine design.

28 May 2021

Will emerging SARS-CoV-2 variants affect T cell immunity? A meta-analysis

New research by a team of scientists at The Hong Kong University of Science and Technology sheds light on the epitopic targets of SARS-CoV-2 by T cells in COVID-19 convalescents. The team’s findings suggest that the epitopes targeted by T cells during infection may not be affected by the emergence of SARS-CoV-2 variants.

28 May 2021

Researchers discover cross-reactive coronavirus antibody triggered during COVID-19 infection

Even before the COVID-19 pandemic, most people in the United States already had been sick with a coronavirus, albeit a far less dangerous one.

28 May 2021

Pfizer-BioNTech COVID-19 vaccine may not be associated with adverse effects on fertility and breastfeeding, says study

A recent study by researchers in Singapore shows the absence of evidence for adverse effects on fertility or the presence of the vaccine mRNA (messenger ribonucleic acid) in breast milk, following the administration of the Pfizer BNT162B2 COVID-19 vaccine. This supports efforts to prevent the spread of false information about the effects of the vaccine.

27 May 2021

New DNA COVID-19 vaccine proven effective in mice

A new study has shown that a new DNA-based COVID-19 vaccine successfully induced immunization against SARS-CoV-2 in mice and hamsters.

27 May 2021

Astodrimer sodium exhibits potent virucidal and antiviral activity against SARS-CoV-2 in vitro

Researchers from the US and Australia recently conducted some studies to assess the in vitro antiviral and virucidal (irreversible) activity of astodrimer sodium against SARS-CoV-2.

26 May 2021

Disproportionate number of SARS-CoV-2 breakthrough infections are caused by variants of concern

A study conducted by researchers in the United States has shown that among twenty patients with breakthrough infection following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – all of the infections were caused by variants of concerns.

26 May 2021

Intensity and duration of SARS-CoV-2 immunity may depend on ABO blood group

A team of scientists from Canada and Spain recently evaluated the durability of antigen-specific immune responses in COVID-19 recovered individuals. They have also identified potential host factors associated with robust and long-lasting anti-SARS-CoV-2 immunity.

26 May 2021

Could GRP78 be a therapeutic target against COVID-19?

A new study by a team of researchers at the Keck School of Medicine, University of Southern California, USA, reports a potentially important therapeutic target in the form of a molecule called GRP78 that promotes the entry and protein production by many viruses. The team's paper has been published in the Journal of Biological Chemistry.

26 May 2021

Tissue-resident memory T cells found in lungs of people who had COVID-19 10 months ago

In recent research by Judith Grau-Expósito et al., scientists identify circulating virus-specific T cell responses during acute SARS-CoV-2 infection with functional, migratory, and apoptotic patterns modulated by viral proteins and associated with clinical outcome.

26 May 2021

Spike Protein News and Research

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

Inflammatory brain injury higher in men with acute COVID-19, finds study

SARS-CoV-2 genome mutations display convergent evolution indicating strong adaptive advantages

Corilagin: could a plant compound used in Chinese herbal medicine help prevent COVID-19?

Researchers identify defensins as potential anti-SARS-CoV-2 agents

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization

New LNP-based mRNA vaccine candidate protects against lethal SARS-CoV-2 in preclinical trials

Loss of gut epithelial barrier responsible for COVID-19-related MIS-C in children, suggests study

Researchers identify a novel SARS-CoV-2 variant (with the V1230L mutation) in West Bengal, India

Study supports single-dose COVID-19 vaccine strategy for previously infected individuals

Identifying SARS-CoV-2 epitopes targeted by current vaccination could help improve future vaccines

Will emerging SARS-CoV-2 variants affect T cell immunity? A meta-analysis

Researchers discover cross-reactive coronavirus antibody triggered during COVID-19 infection

Pfizer-BioNTech COVID-19 vaccine may not be associated with adverse effects on fertility and breastfeeding, says study

New DNA COVID-19 vaccine proven effective in mice

Astodrimer sodium exhibits potent virucidal and antiviral activity against SARS-CoV-2 in vitro

Disproportionate number of SARS-CoV-2 breakthrough infections are caused by variants of concern

Intensity and duration of SARS-CoV-2 immunity may depend on ABO blood group

Could GRP78 be a therapeutic target against COVID-19?

Tissue-resident memory T cells found in lungs of people who had COVID-19 10 months ago

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News